Neurogene Inc. (NGNE)

NASDAQ: NGNE · Real-Time Price · USD

21.11

+1.89 (9.83%)

Aug 13, 2025, 4:00 PM - Market closed

Neurogene Employees

Neurogene had 107 employees as of December 31, 2024. The number of employees increased by 16 or 17.58% compared to the previous year.

Employees

107

Change (1Y)

16

Growth (1Y)

17.58%

Revenue / Employee

n/a

Profits / Employee

-$788,729

Market Cap

301.28M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	107	16	17.58%
Dec 31, 2023	91	9	10.98%
Dec 31, 2022	82	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

NGNE News

2 days ago - Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates - Business Wire
5 days ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
14 days ago - What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Benzinga
6 weeks ago - Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - Business Wire
3 months ago - Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV - Business Wire
3 months ago - Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates - Business Wire
3 months ago - Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting - Business Wire
4 months ago - Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome - Business Wire